CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T
cells to refractory cancers but have shown limited efficacy in persistent, recurrent …
cells to refractory cancers but have shown limited efficacy in persistent, recurrent …
Vascular microenvironment, tumor immunity and immunotherapy
Z Lamplugh, Y Fan - Frontiers in immunology, 2021 - frontiersin.org
Immunotherapy holds great promise for treating cancer. Nonetheless, T cell-based
immunotherapy of solid tumors has remained challenging, largely due to the lack of …
immunotherapy of solid tumors has remained challenging, largely due to the lack of …
Nanotechnology-enhanced immunotherapy for metastatic cancer
P Zhang, J Meng, Y Li, C Yang, Y Hou, W Tang… - The Innovation, 2021 - cell.com
A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective
treatments for metastases are currently lacking due to the difficulty of selectively targeting …
treatments for metastases are currently lacking due to the difficulty of selectively targeting …
Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation
Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
Improving CAR T-cell persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson… - International journal of …, 2021 - mdpi.com
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …
Reactions related to CAR-T cell therapy
L Miao, Z Zhang, Z Ren, Y Li - Frontiers in immunology, 2021 - frontiersin.org
The application of chimeric antigen receptor (CAR) T-cell therapy as a tumor immunotherapy
has received great interest in recent years. This therapeutic approach has been used to treat …
has received great interest in recent years. This therapeutic approach has been used to treat …
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
T Asmamaw Dejenie, M Tiruneh G/Medhin… - Human Vaccines & …, 2022 - Taylor & Francis
Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that
is considered a 'living'and self-replicating drug to treat cancer, sometimes resulting in a …
is considered a 'living'and self-replicating drug to treat cancer, sometimes resulting in a …
CAR T-Cell therapy for the management of mantle cell lymphoma
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-
cells characterized by translocation, which is typically due to excess expression of Cyclin …
cells characterized by translocation, which is typically due to excess expression of Cyclin …